A

Compositions and methods for modulating Ataxin 3 expression

Espacenet Family 58387449

Abstract

Disclosed are methods for modulating splicing of Ataxin 3 mRNA in an animal with modified oligonucleotides. Such compounds and methods are useful to treat, prevent, or ameliorate spinocerebellar ataxia type 3 (SCA3) in an individual in need thereof.

Inventors 5

  1. Rigo, Frank
  2. Prakash, Thazha P.
  3. van Roon-Mom, Wilhelmina Maria Clasina
  4. Lodewijk J.A. Toonen Aachen author as filed: Toonen, Lodewijk Julius Anton
  5. van Roon-Mom, Wilhemina Maria, Clasina

Inventors are linked to an Aachen author when surname and first name match exactly one author.

Applicants

  • IONIS PHARMACEUTICALS, INC.
  • ACADEMISCH ZIEKENHUIS LEIDEN GBS Leiden

Cited papers 0 in the database

Non-patent literature as cited (38)
  • - Evers, M.M. et al. “Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon”. Neurobiology of Disease, Vol. 58 (2013), pp: 49-56; cited on IDS filed 06/07/2024 as NPL# 11. (Year: 2013)
  • - MANOHARAN ET AL., BIOORG. MED. CHEM. LETT., vol. 4, 1994, pages 1053 - 1060
  • - "Remington's Pharmaceutical Sciences", 2005, MACK PUBLISHING CO.
  • - LETSINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6553 - 6556
  • - ZHOU ET AL., J. ORG. CHEM., vol. 74, 2009, pages 118 - 134
  • - FREIER ET AL., NUCLEIC ACIDS RESEARCH, vol. 25, no. 22, 1997, pages 4429 - 4443
  • - ALBAEK ET AL., J. ORG. CHEM., vol. 71, 2006, pages 7731 - 7740
  • - SINGH ET AL., CHEM. COMMUN., vol. 4, 1998, pages 455 - 456
  • - KOSHKIN ET AL., TETRAHEDRON, vol. 54, 1998, pages 3607 - 3630
  • - WAHLESTEDT ET AL., PROC. NATL. ACAD. SCI. U. S. A., vol. 97, 2000, pages 5633 - 5638
  • - KUMAR ET AL., BIOORG. MED. CHEM. LETT., vol. 8, 1998, pages 2219 - 2222
  • - SINGH ET AL., J. ORG. CHEM., vol. 63, 1998, pages 10035 - 10039
  • - SRIVASTAVA ET AL., J. AM. CHEM. SOC., vol. 20017, no. 129, pages 8362 - 8379
  • - ELAYADI ET AL., CURR. OPINION INVENS. DRUGS, vol. 2, 2001, pages 558 - 561
  • - BRAASCH ET AL., CHEM. BIOL., vol. 8, 2001, pages 1 - 7
  • - ORUM ET AL., CURR. OPINION MOL. THER., vol. 3, 2001, pages 239 - 243
  • - FRIEDEN ET AL., NUCLEIC ACIDS RESEARCH, vol. 21, 2003, pages 6365 - 6372
  • - LEUMANN, CJ. BIOORG. & MED. CHEM, vol. 10, 2002, pages 841 - 854
  • - BRAASCH ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 4503 - 4510
  • - KUMAR ET AL., ORG. BIOMOL. CHEM., vol. 11, 2013, pages 5853 - 5865
  • - KABANOV ET AL., FEBS LETT., vol. 259, 1990, pages 327 - 330
  • - ENGLISCH ET AL., ANGEWANDTE CHEMIE, vol. 30, no. 613, 1991
  • - MANOHARAN ET AL., BIOORG. MED. CHEM. LETT., vol. 3, 1993, pages 2765 - 2770
  • - NISHINA ET AL., MOLECULAR THERAPY, vol. 16, 2008, pages 734 - 740
  • - "Carbohydrate Modifications in Antisense Research", ACS SYMPOSIUM SERIES 580, vol. 4, pages 40 - 65
  • - MANOHARAN ET AL., ANN. N.Y. ACAD. SCI., vol. 660, 1992, pages 306 - 309
  • - OBERHAUSER ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 533 - 538
  • - SAISON-BEHMOARAS ET AL., EMBO J., vol. 10, 1991, pages 1111 - 1118
  • - SVINARCHUK ET AL., BIOCHIMIE, vol. 75, 1993, pages 49 - 54
  • - MANOHARAN ET AL., TETRAHEDRON LETT., vol. 36, 1995, pages 3651 - 3654
  • - SHEA ET AL., NUCL. ACIDS RES., vol. 18, 1990, pages 3777 - 3783
  • - MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, vol. 14, 1995, pages 969 - 973
  • - MISHRA ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1264, 1995, pages 229 - 237
  • - CROOKE ET AL., J. PHARMACOL. EXP. THER., vol. 277, 1996, pages 923 - 937
  • - NISHINA ET AL., MOLECULAR THERAPY NUCLEIC ACIDS, vol. 4, 2015
  • - "GENBANK", Database accession no. NT_026437.12
  • - CEMAL ET AL., JACKSON LABORATORY, 2002
  • - HUM MOL GENET, vol. 11, pages 1075 - 1094